BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28059929)

  • 1. Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma.
    Abbott AM; Doepker MP; Kim Y; Perez MC; Gandle C; Thomas KL; Choi J; Shridhar R; Zager JS
    Am J Clin Oncol; 2018 Aug; 41(8):747-753. PubMed ID: 28059929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
    Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.
    Eldredge-Hindy H; Ohri N; Anne PR; Eschelman D; Gonsalves C; Intenzo C; Bar-Ad V; Dicker A; Doyle L; Li J; Sato T
    Am J Clin Oncol; 2016 Apr; 39(2):189-95. PubMed ID: 24441583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).
    Dhir M; Zenati MS; Jones HL; Bartlett DL; Choudry MHA; Pingpank JF; Holtzman MP; Bahary N; Hogg ME; Zeh HJ; Geller DA; Wallis Marsh J; Tsung A; Zureikat AH
    Ann Surg Oncol; 2018 Feb; 25(2):550-557. PubMed ID: 29181682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
    Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
    Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.
    Yamamoto A; Chervoneva I; Sullivan KL; Eschelman DJ; Gonsalves CF; Mastrangelo MJ; Berd D; Shields JA; Shields CL; Terai M; Sato T
    Radiology; 2009 Jul; 252(1):290-8. PubMed ID: 19561263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
    Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
    Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.
    Dabrowiecki A; Sankhla T; Shinn K; Bercu ZL; Ermentrout M; Shaib W; Cardona K; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1006-1014. PubMed ID: 32367230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
    Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
    Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A; Haug AR; Zech CJ; Schaller UC
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
    Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
    J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
    Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
    Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.
    Arulananda S; Parakh S; Palmer J; Goodwin M; Andrews MC; Cebon J
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1183. PubMed ID: 32721131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
    Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
    Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
    Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
    Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
    Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
    Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
    Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
    Estler A; Artzner C; Bitzer M; Nikolaou K; Hoffmann R; Hepp T; Hagen F; Eigentler T; Forschner A; Grözinger G
    Acta Radiol; 2022 May; 63(5):577-585. PubMed ID: 34034537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.
    Gonsalves CF; Eschelman DJ; Adamo RD; Anne PR; Orloff MM; Terai M; Hage AN; Yi M; Chervoneva I; Sato T
    Radiology; 2019 Oct; 293(1):223-231. PubMed ID: 31453767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.